- Home
- HRMY vs SUPN Comparison
HRMY vs SUPN Comparison
Compare HRMY & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- SUPN
- Stock Information
- Founded
- HRMY 2017
- SUPN 2005
- Country
- HRMY United States
- SUPN United States
- Employees
- HRMY N/A
- SUPN N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- HRMY Health Care
- SUPN Health Care
- Exchange
- HRMY Nasdaq
- SUPN Nasdaq
- Market Cap
- HRMY 1.9B
- SUPN 1.9B
- IPO Year
- HRMY 2020
- SUPN 2012
- Fundamental
- Price
- HRMY $34.83
- SUPN $36.43
- Analyst Decision
- HRMY Buy
- SUPN Hold
- Analyst Count
- HRMY 10
- SUPN 1
- Target Price
- HRMY $49.80
- SUPN $36.00
- AVG Volume (30 Days)
- HRMY 539.5K
- SUPN 348.4K
- Earning Date
- HRMY 02-20-2025
- SUPN 02-25-2025
- Dividend Yield
- HRMY N/A
- SUPN N/A
- EPS Growth
- HRMY N/A
- SUPN 130.79
- EPS
- HRMY 2.11
- SUPN 1.07
- Revenue
- HRMY $681,879,000.00
- SUPN $651,972,000.00
- Revenue This Year
- HRMY $24.83
- SUPN $7.82
- Revenue Next Year
- HRMY $18.66
- SUPN N/A
- P/E Ratio
- HRMY $16.53
- SUPN $34.05
- Revenue Growth
- HRMY 25.83
- SUPN 6.79
- 52 Week Low
- HRMY $28.14
- SUPN $25.53
- 52 Week High
- HRMY $41.61
- SUPN $39.37
- Technical
- Relative Strength Index (RSI)
- HRMY 55.30
- SUPN 52.26
- Support Level
- HRMY $33.36
- SUPN $35.73
- Resistance Level
- HRMY $34.96
- SUPN $37.34
- Average True Range (ATR)
- HRMY 1.19
- SUPN 1.20
- MACD
- HRMY 0.16
- SUPN -0.01
- Stochastic Oscillator
- HRMY 81.62
- SUPN 69.02
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.